If you've spent any time on longevity Twitter, walked through a high-end vitamin shop, or watched the supplement aisle at Whole Foods, you've seen the same three letters everywhere: NAD+, NMN, NR. The bottles all promise something similar (more energy, slower aging, better cellular function), and yet they cost wildly different amounts and contain entirely different molecules. To make it more confusing, none of them are technically the same as NAD+ itself. NMN and NR are precursors. Most of what's labeled "NAD+" in commerce is something else.

So which one actually does what people hope it does? Which is most worth your money? And does the choice really matter, or is it just biotech marketing?

Here's a clear breakdown of what each molecule is, how they relate, what the human research actually shows, and how to think about choosing between them.

The short answer

NAD+ is the final coenzyme your cells use for energy and DNA repair. NMN and NR are precursor molecules your body converts to NAD+ through the salvage pathway. Most of the human evidence that NAD+ supplementation actually works comes from oral NR and NMN trials, both of which reliably raise circulating NAD+ levels at doses of 300 to 1000 mg per day. A 2026 head-to-head Norwegian study found NR produced roughly 2.3 times the blood NAD+ increase of NMN at the same gram dose. A separate Nestlé-led study found both raised NAD+ comparably after 14 days. The differences between the two are real but not as large as the differences between either of them and doing nothing.

The biology in one paragraph

Your body builds NAD+ through three main pathways: de novo synthesis (from the amino acid tryptophan), the salvage pathway (recycling nicotinamide), and the Preiss-Handler pathway (from niacin). The salvage pathway, which recycles existing nicotinamide back into NAD+, is the dominant route in most cells. NMN and NR both enter the salvage pathway, but at different points. NR enters the cell through dedicated nucleoside transporters, where it gets converted to NMN inside the cell. NMN, despite being one biochemical step closer to NAD+, has historically been thought to require conversion back to NR before crossing the cell membrane, although the discovery of a dedicated NMN transporter in 2019 complicated that picture.

NAD+: the final coenzyme

NAD+ is what your cells actually use. It's the active coenzyme that drives oxidative phosphorylation in mitochondria, fuels sirtuin enzymes that govern aging and gene expression, and powers PARP enzymes that repair DNA damage. Without sufficient NAD+, your cells cannot produce energy efficiently, cannot maintain DNA integrity, and cannot run the longevity-relevant maintenance programs that keep aging in check.

The problem is that NAD+ itself is not effectively absorbed when taken orally. It's a large, charged molecule that breaks down in the digestive tract. Most "NAD+ supplements" on the market are either (a) actually NMN or NR sold under the broader NAD+ name, or (b) NAD+ that doesn't usefully reach your cells in functional form. This is why injectable NAD+ exists as a separate category: it bypasses the gut entirely.

For oral supplementation, the strategy is always to use a precursor that your body can convert. That's where NMN and NR come in.

NR: the well-studied veteran

Nicotinamide riboside (NR) was discovered as an NAD+ precursor in 2004 and brought to commercial supplementation through licensing of patents originally held by Dartmouth. It's been the most extensively studied NAD+ precursor in humans for the longest time. Multiple placebo-controlled trials at doses of 300 to 1000 mg per day have shown NR raises circulating NAD+ reliably.

What NR has going for it:

Critiques of NR center on cost per gram (typically higher than NMN), the indirect biosynthesis pathway requiring conversion through NMN before becoming NAD+, and the lack of breakthrough functional data in healthy aging populations beyond the surrogate marker of blood NAD+ elevation.

NMN: the high-profile newcomer

Nicotinamide mononucleotide (NMN) is one biochemical step closer to NAD+ than NR. It became publicly famous largely through the advocacy of Harvard's David Sinclair, who's been publicly taking NMN for years and writing about its potential. The mouse data on NMN is impressive: studies have shown improvements in mitochondrial function, exercise capacity, insulin sensitivity, and several aging biomarkers in aged mice given NMN.

What NMN has going for it:

Critiques of NMN center on the fact that until recently, fewer high-quality independent human trials existed compared to NR. The Slc12a8 transporter findings have not been replicated in all tissues, and some research suggests most ingested NMN may be converted to NR before crossing cell membranes. The 2026 University of Bergen study found NR raised blood NAD+ more than NMN at matched doses, raising questions about whether NMN's "one step closer" advantage holds up in practice.

What the head-to-head trials show

For years, direct comparisons between NR and NMN in humans didn't exist. That's changed in the last 18 months. Two key studies define the current state of the comparison:

The Nestlé-led parallel-group study (2026). This was a 14-day, placebo-controlled study in 65 adults. Participants received either 1 gram NR, 1 gram NMN, 0.5 grams nicotinamide, or placebo daily. Both NR and NMN approximately doubled circulating NAD+ levels by day 14. Nicotinamide did not. The conclusion was that NR and NMN have similar effects on sustained NAD+ elevation. The study also identified an interesting mechanism: gut bacteria appear to convert both NR and NMN into nicotinic acid, which then drives systemic NAD+ elevation.

The University of Bergen crossover study (2026). This study used a within-subject crossover design (each participant received both NR and NMN at different times). NR raised whole-blood NAD+ from a baseline of ~27 µM to 70.5 µM by day 8, an increase of about 161%. NMN raised blood NAD+ from ~32 µM to 53.7 µM, an increase of about 69%. Head-to-head, NR produced approximately 2.3 times the NAD+ increase of NMN at the same gram dose, even when corrected for molecular weight. NR also raised brain NAD+ after 4 weeks of supplementation.

Why the discrepancy? The two studies used different designs. The crossover design in the Bergen study is generally considered more sensitive to per-individual differences. The parallel-group design in the Nestlé study may have been underpowered to detect differences between precursors. The honest synthesis is that both precursors work, NR may have the edge on blood NAD+ elevation per gram, and the magnitude of the difference depends on the methodology you trust most.

Bioavailability isn't everything

It's tempting to conclude that NR is just better because it raises blood NAD+ more. But blood NAD+ is a surrogate marker. What ultimately matters is tissue NAD+ in the organs that drive aging-related decline (brain, heart, muscle, liver, kidneys) and the functional outcomes that follow. We don't yet have head-to-head trials that compare NR and NMN on functional endpoints in healthy aging populations.

There are scenarios where the choice might shift:

If brain support is a primary goal, NR has demonstrated brain NAD+ elevation in human studies, while NMN's brain penetration is less well documented.

If muscle health is a primary goal, NMN has more direct evidence of muscle insulin sensitivity improvements in postmenopausal women, and some studies suggest superior performance on muscle strength endpoints.

If you want the strongest cumulative human research base, NR has the longest track record of published trials.

If you want the option that aligns with most current longevity clinic protocols, NMN is often the default choice, partly because of Sinclair's advocacy and partly because of the proximity-to-NAD+ argument.

What about combining them?

Some protocols combine NR and NMN, hypothesizing that they may activate different aspects of the salvage pathway in different tissues. The published research on combination protocols is thin. The argument for combining is mechanistic and plausible. The argument against is cost: you're paying for two precursors when one would likely do most of the work. Most clinicians who use NAD+ precursors as part of structured longevity protocols pick one and dose it consistently, often combined with other interventions (NAD+ injections, sirtuin activators, exercise) rather than stacking precursors.

Where do injectable NAD+ and IV NAD+ fit?

Both NR and NMN are oral. They depend on your body's biosynthesis pathway to convert them into NAD+. Injectable NAD+ skips that step entirely. The pharmacokinetic ceiling on what oral precursors can do is real, and once you've optimized your oral protocol, the next step up is parenteral delivery.

The relationship looks like this: oral precursors raise NAD+ through your body's natural biosynthesis (modest, sustained elevation). Subcutaneous and IM injections deliver NAD+ directly into circulation, achieving much higher plasma levels. IV infusions go further still, hitting plasma concentrations that no other route can match. Each format has trade-offs in cost, convenience, and bioavailability, and the right choice depends on goals and clinical supervision.

Dosing in practice

Common protocols in 2026:

Higher is not always better. The benefit curve appears to flatten at higher oral doses, and side effects (mild GI symptoms, occasional headache) become more common. Most clinicians settle patients at an effective oral dose and then layer injectable protocols on top for additional bioavailability rather than escalating oral dosing endlessly.

Frequently asked questions

Is NMN better than NR? The honest answer in 2026 is that both reliably raise blood NAD+, and the recent head-to-head data slightly favors NR on a per-gram basis. The functional differences in long-term outcomes are not yet established.

Can I just take NAD+ directly? Not effectively, orally. The molecule is too large and unstable to absorb intact. "NAD+" labeled oral supplements are either misnamed (actually a precursor) or unlikely to deliver useful NAD+. For direct NAD+, injectable or IV is the only effective route.

Do liposomal or sublingual formulations matter? They likely deliver higher peak blood concentrations than standard capsules, but whether that translates into better outcomes is not yet established in head-to-head trials. You're paying for theoretical bioavailability gains that may or may not produce meaningfully different results.

Are NMN supplements safe? Yes, in clinical trials at doses up to 2 grams per day. The FDA has taken regulatory action against marketing NMN as a dietary supplement (a position the supplement industry has contested), which has created retail availability uncertainty for some products. NMN remains widely available through 503A compounding pharmacies and various supplement channels.

How long until I notice anything? Most people don't notice acute effects from oral precursors. Subtle improvements in energy, sleep quality, or recovery may emerge over weeks to months. Injectable forms typically produce more rapid subjective changes, often within the first few doses.

The Bottom Line

NAD+ is the end goal. NMN and NR are precursors your body converts to NAD+. Both work. NR has slightly stronger human research on blood NAD+ elevation per gram dose, but NMN has equivalent effectiveness in other study designs and arguably better muscle endpoint data. The choice is less important than the broader strategy: if you're optimizing NAD+, the foundational behaviors (exercise, sleep, nutrition) come first, oral precursors are a reasonable next step, and injectable protocols are the format of choice for sustained higher-level elevation.

If you're considering an injectable NAD+ protocol that complements oral supplementation, CLYR Health offers physician-supervised NAD+ injections through a licensed 503A pharmacy. Start your assessment.